SC
SCNX.US Scienture Holdings, Inc.
- Market cap
- USD 4.93M
- P/E
- -
- P/B
- 0.09x
- ROE
- -13,654.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SCNX.US undervalued?
Graham numberThe Graham number of Scienture Holdings, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Scienture Holdings, Inc. fundamental analysis
No fundamental analysis for Scienture Holdings, Inc. yet.
Scienture Holdings, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-…
Full company profileScienture Holdings, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Scienture Holdings, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.48M | 2.93M | 3.83M | 7.44M | 17.1M | 9.89M | 10.3M | 1.36M | 137K | 432K | 1.67B |
| Gross Profit | 2.47M | 2.93M | 3.38M | 4.87M | 5.71M | 4.75M | 5.52M | 49.0K | 6.01K | 331K | 1.36B |
| Operating Income | -1.01M | 395K | -87.6K | 125K | -2.51M | -5.29M | -2.92M | -4.40M | -14.7M | -16.2M | -7.33B |
| EBITDA | -1.02M | 446K | 66.6K | -136K | -2.40M | -5.15M | -1.87M | -6.29M | -17.4M | -38.9M | -7.33B |
| Net Income | -2.76M | 289K | 9.04K | -284K | -2.54M | -5.32M | -3.47M | -17.8M | 9.07M | -41.5M | -8.02B |
| EPS | -197 | 19 | 0.58 | -18 | -123 | -245 | -154 | -187 | 62 | -6.76 | -5,022 |
| Balance Sheet | |||||||||||
| Total Assets | 337K | 617K | 2.23M | 5.57M | 9.79M | 5.77M | 3.71M | 12.5M | 105M | 84.2M | 87.2M |
| Total Liabilities | 1.49M | 929K | 1.38M | 1.43M | 1.11M | 2.00M | 3.37M | 12.0M | 25.8M | 14.1M | 28.4M |
| Shareholders' Equity | -1.15M | -312K | 845K | 4.14M | 8.68M | 3.77M | 763K | 542K | 79.1M | 70.1M | 58.7M |
| Cash & Short-term Investments | 14.7K | 184K | 870K | 2.87M | 5.92M | 3.12M | 1.09M | 314.00 | 308K | 6.66M | 4.75M |
| Total Debt | 781K | 666K | 844K | 998K | 627K | 1.25M | 1.58M | 6.76M | 3.53M | 24.1K | 9.36M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.31M | 172K | 273K | 142K | -2.21M | -2.57M | -1.56M | -2.23M | -14.3M | -13.4M | -12.7B |
| Capital Expenditure | 0.00 | 0.00 | 15.0K | 82.3K | 37.5K | 22.6K | 451K | 2.00 | 12.0K | 3.00 | 13.33 |
| Free Cash Flow | -1.31M | 172K | 258K | 59.5K | -2.25M | -2.59M | -1.56M | -2.23M | -14.3M | -13.4M | -12.7B |
| Ratios | |||||||||||
| ROE | - | - | 1.1% | -6.9% | -29.2% | -141.0% | -455.0% | -3,290.0% | 11.5% | -59.2% | -13,654.1% |
| ROA | -818.7% | 46.8% | 0.4% | -5.1% | -25.9% | -92.2% | -93.6% | -142.4% | 8.6% | -49.3% | -9,199.9% |
| Net Profit Margin | -111.2% | 9.9% | 0.2% | -3.8% | -14.8% | -53.8% | -33.9% | -1,308.3% | 6,634.7% | -9,618.0% | -479.3% |
| Debt to Equity | - | - | 1.00x | 0.24x | 0.07x | 0.33x | 2.08x | 12.47x | 0.04x | 0.00x | 0.16x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Scienture Holdings, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 19, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 14.9M | 102 | 163.9% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:25 on Oct 5, 2026.
Who owns Scienture Holdings, Inc.
- Insiders 22.25%
- Institutions 4.92%
- Public & others 72.84%
- Shares outstanding 1.79M
- Free float 1.28M
Top funds holding SCNX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 165K | 0.40% | -0.21% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 102K | 0.25% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 53.5K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 45.4K | 0.11% | 0.00% | Sep 2026 |
Top institutions holding SCNX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 510K | 1.24% | +25.07% | Jun 2026 |
| Geode Capital Management, LLC | 335K | 0.82% | -22.49% | Jun 2026 |
| Susquehanna International Group, LLP | 235K | 0.57% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 198K | 0.48% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 165K | 0.40% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 133K | 0.32% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 105K | 0.26% | +119.80% | Jun 2026 |
| Northern Trust Corp | 87.6K | 0.21% | +530.53% | Jun 2026 |
| UBS Group AG | 85.9K | 0.21% | -20.33% | Jun 2026 |
| Jane Street Group LLC | 75.7K | 0.18% | +174.02% | Jun 2026 |
| Virtu Financial LLC | 47.6K | 0.12% | -43.53% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 33.3K | 0.08% | -8.68% | Jun 2026 |
| Private Advisor Group, LLC | 15.0K | 0.04% | 0.00% | Jun 2026 |
| Barclays PLC | 133.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 64.00 | 0.00% | +16.36% | Jun 2026 |
| Nova Wealth Management, Inc. | 30.00 | 0.00% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Scienture Holdings, Inc. company profile
- Company name
- Scienture Holdings, Inc.
- Ticker
- SCNX.US
- Exchange
- USA Stocks
- Listed since
- Apr 27, 2010
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 4
- Fiscal year end
- December
- Address
- 20 Austin Boulevard, Commack, NY, United States, 11725
- Phone
- 631 670 6039
- Website
- scienture.com
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Scienture Holdings, Inc. management
4- Dr. Shankar Hariharan Ph.D.Founder, Co-CEO & Executive Chairman · born 1957
- Dr. Narasimhan Mani M.B.A., Ph.D.President, Co-CEO, Interim CFO & Director · born 1974
- Mr. Rahul Surana M.B.A., Ph.D.Executive VP & COO of Scienture LLC
- Ms. Michele RathSenior VP & Chief Commercial Officer of Scienture LLC